Lung Cancer | Specialty

Nondriver mNSCLC: Incorporating Trial Data into Practice

July 10th 2018

Non-Small Cell Lung Cancer: Other Actionable Mutations

July 10th 2018

Molecular Testing's Role in Non-Small Cell Lung Cancer

July 10th 2018

Managing the IMpower 150 Regimen in Nonsquamous mNSCLC

July 10th 2018

IMpower150: Quadruplet Therapy for Nonsquamous mNSCLC

July 10th 2018

CheckMate-227: Nivolumab + Ipilimumab in mNSCLC

July 10th 2018

Quality of Life's Role in Treating Nondriver mNSCLC

July 10th 2018

Frontline Therapeutic Decisions for Nondriver mNSCLC

July 10th 2018

Chemotherapy + Pembrolizumab: A New Standard of Care?

July 10th 2018

Optimizing Use of the KEYNOTE-189 Regimen in mNSCLC

July 10th 2018

KEYNOTE-189: Chemotherapy and Pembrolizumab in mNSCLC

July 10th 2018

Nondriver Metastatic NSCLC: Evolving Treatment Paradigm

July 10th 2018

Bauml Discusses State of Immunotherapy Biomarkers in NSCLC

July 10th 2018

Joshua Bauml, MD, discusses the limitations of PD-L1 and tumor mutational burden as immunotherapy biomarkers in non–small cell lung cancer and emerging biomarkers showing promise in the field.

Dr. Liu on Potentially Promising Combinations in ALK-Positive NSCLC

July 7th 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses potentially promising combinations in ALK-positive non–small cell lung cancer (NSCLC).

Liu Looks Beyond Resistance in ALK-Translocated NSCLC

July 6th 2018

Stephen Liu, MD, addresses the use of available therapies and the methods of overcoming acquired resistance in patients with ALK-positive non–small cell lung cancer.

Dr. Kosteva on Single-Agent Versus Combination Immunotherapy in NSCLC

July 5th 2018

John A. Kosteva, MD, clinical assistant professor of medicine, University of Pennsylvania School of Medicine, Abramson Cancer Center, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer (NSCLC).

Dr. Bauman on Treatments for Patients With BRAF-Mutant NSCLC

July 4th 2018

Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).

Dr. Levy on the Application of Liquid Biopsies in NSCLC

July 4th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the application of liquid biopsies in non–small-cell lung cancer (NSCLC).

Dr. El-Deiry on Liquid Vs Tissue Biopsies

July 3rd 2018

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses the advantages of liquid biopsies over tissue biopsies.

Garassino Highlights ASCO NSCLC Findings and Looks to the Future

July 3rd 2018

Marina Chiara Garassino, MD, reflects on the first-line approval of osimertinib, recent data with durvalumab, and the promise for combination chemoimmunotherapy in patients with non–small cell lung cancer.